Linscomb Wealth’s Evogene EVGN Stock Holding History

Linscomb Wealth’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,000	Closed	-$7K	–	298
2022 Q4	$7K	Buy	+1,000	New	+$7.05K	﹤0.01%	334

Other funds holding EVGN

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

JIC

Joel Isaacson & Co New York $3.02B AUM 21.81% 1-Year Est. Return

CAG

Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Linscomb Wealth's EVGN Position: Q1 2023 in Review

Linscomb Wealth sold out of Evogene (EVGN) in Q1 2023, closing a stake of 1,000 shares — an estimated $7K sold.

Linscomb Wealth first reported a position in EVGN in Q4 2022 and held it in 1 quarter. The position peaked at $7K in Q4 2022. 27 funds tracked by Wall St. Rank hold EVGN as of Q1 2023.

Linscomb Wealth reported no remaining Evogene position as of Q1 2023 after selling out during the quarter.
Linscomb Wealth sold 1,000 Evogene shares in Q1 2023, an estimated $7K.
Linscomb Wealth first reported a position in Evogene in Q4 2022 and held it in 1 quarter.
Linscomb Wealth's Evogene position peaked at $7K in Q4 2022.
27 funds tracked by Wall St. Rank held Evogene as of Q1 2023.

Based on Linscomb Wealth's 13F filing for Q1 2023, filed 11 May 2023.